---

To study early and late effect of intravitreal injection Ranibizumab on Cystoid Macular Edema(CME) due to Branch Retinal Vein Occlusion (BRVO)

---

Original Article

Author Details : Ram Yash Singh Yadav, Anil Kumar*, Ram Kumar, Ashutosh Kumar Singh, Chiranjee Rai

Volume : 7, Issue : 1, Year : 2021

Article Page : 194-198

https://doi.org/10.18231/j.ijceo.2021.041

Suggest article by email

Get Permission

---

Abstract

Objective: To study early and late effect of intravitreal injection Ranibizumab on Cystoid Macular Edema(CME) because of Branch Retinal Vein Occlusion (BRVO).
Materials and Methods: This Study included 25 Patients (age group18 year) with cystoid macular edema because of branch retinal vein occlusion attending to department of ophthalmology Nehru Chikitsalaya, B.R.D. Medical college, Gorakhpur. An observational study has been concluded in which early and late effect of intravitreal injection Ranibizumab on cystoid macular edema because of branch retinal vein occlusion.
Result: The mean age group being 58.53 year of total 25 patients with 13 male and 12 female patients with no dropout throughout the study. In 1 month of post injecton observation, 10 (40%) patients who presented within 1 month of onset of BRVO showed more gain in visual acuity and more reduction in central macular thickness (CMT) as compare to 15 (60%) patients who presented after 1 month of onset of BRVO.
Conclusion: Intravitreal Ranibizumab is more effective in patients presented early than late in improving best corrected visual acuity ( BCVA) and decreasing CMT.

Keywords: Best corrected visual acuity, Branch retinal vein occlusion, Central macular thickness, Cystoid macular edema, Intravitreal ranabizumab.

How to cite : Yadav R Y S, Kumar A , Kumar R, Singh A K, Rai C , To study early and late effect of intravitreal injection Ranibizumab on Cystoid Macular Edema(CME) due to Branch Retinal Vein Occlusion (BRVO). Indian J Clin Exp Ophthalmol 2021;7(Special Issue):194-198

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.